Genentech to Invest $750M in Oregon Device Manufacturing Hub
Event summary
- Genentech will invest $750M in a new device fill-finish facility in Hillsboro, Oregon, adding end-to-end manufacturing capabilities to its 75-acre campus.
- The expansion will create 250 high-wage manufacturing jobs and 200 construction jobs, with commercial operations beginning in 2031.
- The facility will support advanced drug delivery devices like pre-filled syringes and autoinjectors across oncology, immunology, and neurology portfolios.
- This follows Genentech's recent manufacturing facility expansion in Holly Springs, North Carolina, as part of Roche's broader U.S. manufacturing commitment.
The big picture
This expansion underscores Roche's commitment to strengthening U.S. biomanufacturing capabilities amid global supply chain uncertainties. The $750M investment reflects a strategic bet on advanced drug delivery devices, which are increasingly critical for patient convenience and treatment adherence. With 13 U.S. manufacturing sites already in operation, Roche is positioning itself to support a growing pipeline of innovative medicines while mitigating geopolitical risks in pharmaceutical production.
What we're watching
- Supply Chain Strategy
- How this expansion integrates with Roche's broader U.S. manufacturing network and whether it signals a shift toward regionalized production.
- Pipeline Flexibility
- The pace at which Genentech can adapt the facility to evolving portfolio needs across high- and low-volume device filling.
- Regional Competitiveness
- Whether Oregon can sustain its attractiveness for biotech manufacturing investments amid growing state-level competition.
Related topics